Hhlr Advisors, Ltd. Prelude Therapeutics Inc Transaction History

Hhlr Advisors, Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$28.63 - $44.3 $1.24 Million - $1.91 Million	-43,169 Reduced 6.89%	583,333 $16.7 Million
Q1 2021 May 17, 2021	SELL	$39.27 - $91.68 $4.85 Million - $11.3 Million	-123,498 Reduced 16.47%	626,502 $27.1 Million
Q3 2020 Nov 16, 2020	BUY	$26.2 - $30.13 $19.7 Million - $22.6 Million	750,000 New	750,000 $22.6 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.